首页 | 本学科首页   官方微博 | 高级检索  
     

孟鲁斯特钠联合布地奈德和复方异丙托溴铵治疗婴幼儿毛细支气管炎的疗效观察
引用本文:欧有平. 孟鲁斯特钠联合布地奈德和复方异丙托溴铵治疗婴幼儿毛细支气管炎的疗效观察[J]. 现代药物与临床, 2016, 31(3): 375-378. DOI: 10.7501/j.issn.1674-5515.2016.03.025
作者姓名:欧有平
作者单位:遂川县妇幼保健院,江西遂川,343900
摘    要:目的观察孟鲁斯特钠联合布地奈德和复方异丙托溴铵治疗婴幼儿毛细支气管炎的临床疗效。方法选取2014年1—12月遂川县妇幼保健院收治的毛细支气管炎患儿120例,分为对照组和治疗组,每组各60例。对照组在常规治疗基础上雾化吸入用布地奈德混悬液0.5 mg和吸入用复方异丙托溴铵溶液1.25 m L,用生理盐水稀释到2 m L,2次/d;治疗组在对照组的基础上口服孟鲁司特钠咀嚼片,6个月以下患儿2 mg/次,6个月~1岁患儿3 mg/次,每晚1次。疗程至症状和体征消失后一周。观察两组患儿治疗后的临床疗效和临床症状。结果治疗后,对照组和治疗组的总有效率分别为85.0%、98.3%,两组比较差异具有统计学意义(P0.05)。治疗组患儿的呼吸困难、气喘、喘鸣音、湿性罗音、咳嗽消失时间及住院时间均比对照组缩短,两组比较差异有统计学意义(P0.05)。结论孟鲁斯特钠联合布地奈德和复方异丙托溴铵治疗婴幼儿毛细支气管炎疗效显著,能迅速改善患儿的临床症状,不良反应较少,具有一定的临床推广应用价值。

关 键 词:孟鲁司特钠咀嚼片  吸入用布地奈德混悬液  吸入用复方异丙托溴铵溶液  毛细支气管炎  婴幼儿
收稿时间:2015-10-22

Clinical observation of montelukast sodium combined with budesonide and compound ipratropium bromide in treatment of infants with capillary bronchitis
OU You-ping. Clinical observation of montelukast sodium combined with budesonide and compound ipratropium bromide in treatment of infants with capillary bronchitis[J]. Drugs & Clinic, 2016, 31(3): 375-378. DOI: 10.7501/j.issn.1674-5515.2016.03.025
Authors:OU You-ping
Affiliation:Suichuan County Maternal and Child Health Hospital, Suichuan 343900, China
Abstract:Objective To observe the curative effect of montelukast sodium combined with budesonide and compound ipratropium bromide in treatment of infants with capillary bronchitis. Methods Infants (120 cases) with capillary bronchitis in Suichuan County Maternal and Child Health Hospital from January 2014 to December 2014 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in control group were aerosol inhalation administered with Budesonide Suspension for inhalation 0.5 mg and Compound Ipratropium Bromide Solution for inhalation 1.25 mL, diluted to 2 mL with 0.9% normal saline on the basis of conventional treatment, twice daily. Patients in treatment group were po administered with Montelukast Sodium Chewable Tablets on the basis of control group once daily at night. The amounts of drugs were corresponding with ages of children, such as below six months children had 2 mg/time, but six months to one years old children had 3 mg/time. The two groups were treated until symptoms and signs disappeared for one week. After treatment, the efficacy and disappeared time of dyspnea, asthma, wheezing rales, moist rales, and cough were evaluated. Results After treatment, the efficacies in the control and treatment groups were 85.0% and 98.3%, respectively, and there were significant differences between two groups (P < 0.05). After treatment, disappear time of dyspnea, asthma, wheezing rales, moist rales, and cough were significantly shorter than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Montelukast sodium combined with budesonide and compound ipratropium bromide has good effect in treatment of infants with capillary bronchitis, and can improve clinical symptoms rapidly, and less adverse reactions, which has a certain clinical application value.
Keywords:Montelukast Sodium Chewable Tablets  Budesonide Suspension for inhalation  Compound Ipratropium Bromide Solution for inhalation  capillary bronchitis  infants
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号